> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Extends Expiration Dating on Bivigam
- URL: https://www.fdaweb.com/fda-extends-expiration-dating-on-bivigam/
- Published: 2022-05-11T12:00:00.000Z
- Updated: 2026-09-14T17:44:09.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5151797

FDA has approved an ADMA Biologics request to extend the expiration date from 24 to 36 months for Bivigam (immune globulin intravenous), indicated for treating primary humoral immunodeficiency. An [FDA notice](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/expiration-date-extension-120-bivigam-immune-globulin-intravenous-human-10-liquid-lots-manufactured?ref=fdaweb.com) says the new expiration date is valid for 120 Bivigam lots that were manufactured and distributed in 2020-2022\. Future lots will be labeled according to the new dating period, it says.